Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „sunitinib“
Suchtreffer
Begriffe & Kennungen
Avastin · 4.5 · Combination of bevacizumab and sunitinib malate In two clinical trials of metastatic renal cell carcinoma, mic
Eintrag öffnenAvastin · 4.8 · Vascular disorders Renal thrombotic microangiopathy with or without concomitant sunitinib use, and hyaline occ
Eintrag öffnenMvasi · 4.5 · Combination of bevacizumab and sunitinib malate
Eintrag öffnenSunitinib
Eintrag öffnenSutent · 4.5 · 8 Medicinal products that may increase sunitinib plasma concentrations Effect of CYP3A4 inhibitors In healthy
Eintrag öffnenSutent · 4.5 · Administration of sunitinib with potent CYP3A4 inducers (e.g., dexamethasone, phenytoin, carbamazepine, rifamp
Eintrag öffnenSutent · 4.5 · Administration of sunitinib with potent CYP3A4 inhibitors (e.g., ritonavir, itraconazole, erythromycin, clarit
Eintrag öffnenSutent · 4.5 · Medicinal products that may decrease sunitinib plasma concentrations Effect of CYP3A4 inducers In healthy volu
Eintrag öffnenSutent · 4.8 · 13 capecitabine. Hyperthyroidism was reported in 4 (1.7%) patients on sunitinib and no patients on capecitabin
Eintrag öffnenSutent · 4.8 · 14 Thirteen patients (3%) receiving sunitinib in the Phase 3 treatment-naïve MRCC study and 4 patients (2%) on
Eintrag öffnenSutent · 4.8 · A Phase 1 dose-escalation study of oral sunitinib was conducted in 35 patients comprised of 30 paediatric pati
Eintrag öffnenSutent · 4.8 · Approximately 22.2% of patients with solid tumours, including GIST and MRCC, who received sunitinib in clinica
Eintrag öffnenSutent · 4.8 · Bleeding events were reported in 18% of patients receiving sunitinib in a Phase 3 GIST study vs 17% of patient
Eintrag öffnenSutent · 4.8 · Endocrine disorders Hypothyroidism was reported as an adverse reaction in 7 patients (4%) receiving sunitinib
Eintrag öffnenSutent · 4.8 · Gastrointestinal disorders Pancreatitis has been observed uncommonly (< 1%) in patients receiving sunitinib fo
Eintrag öffnenSutent · 4.8 · In patients who received sunitinib in Phase 3 registrational studies, pulmonary events (i.e. dyspnoea, pleural
Eintrag öffnenSutent · 4.8 · Long-term safety in MRCC The long-term safety of sunitinib in patients with MRCC was analysed across 9 complet
Eintrag öffnenSutent · 4.8 · Nervous system disorders In clinical studies of sunitinib and from postmarketing surveillance, there have been
Eintrag öffnenSutent · 4.8 · Paediatric population The safety profile of sunitinib has been derived from a Phase 1 dose-escalation study, a
Eintrag öffnenSutent · 4.8 · Patients who presented with pulmonary embolism within the previous 12 months were excluded from sunitinib clin
Eintrag öffnen